Harga Saham & Berita GlobeImmune Inc (GBIM)

GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen. The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before. With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010. As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia

Perihal GlobeImmune Inc

CEO-

Pekerja22

Diasaskan1 Jan 1995

Ibu pejabatLouisville, Colorado, Amerika Syarikat

Sektor-

Laman webglobeimmune.com


Hasil
Kos barangan yang dijual
Kos hasil
Perbelanjaan penyelidikan dan pembangunan
Jumlah perbelanjaan penyelidikan dan pembangunan
Perbelanjaan jualan, am dan pentadbiran
Belanja kendalian
Jumlah belanja kendalian
Pendapatan kendalian
Pendapatan bukan kendalian lain
EBT termasuk item luar biasa
EBT tidak termasuk item luar biasa
Belanja cukai pendapatan
Kadar cukai berkesan
Belanja kendalian lain
Pendapatan bersih
Margin untung bersih
Perolehan bagi setiap syer
Pendapatan faedah dan pelaburan
Belanja faedah
Belanja faedah bersih
Caj susut nilai dan pelunasan
EBITDA
Keuntungan atau kerugian daripada jualan aset

Tanya apa-apa sahaja